Alpha-Emitter Dosimetry and Microdosimetry

Introduction

Alpha-particle therapy is potent because alpha particles deposit energy densely over a few cell diameters—and that same property makes alpha dosimetry a two-scale problem. At the macroscopic scale, the MIRD schema gives a mean absorbed dose to organs and lesions; at the microscopic scale, a single alpha track across a cell nucleus can deliver a fraction of a gray, so the dose is profoundly nonuniform and the biological effect per gray is several times higher than for beta radiation. ^{1, 2}

Targeted alpha therapy (TAT) with radionuclides such as radium-223, actinium-225, astatine-211, and lead-212 has moved from concept to clinic, and with it the need to quantify absorbed dose defensibly. ^{1, 2} Unlike the beta emitters that dominate radioligand therapy, alpha emitters cannot be treated as a smooth, organ-averaged dose and left there. Their short range, their high linear energy transfer (LET), their multi-alpha decay chains, and their elevated relative biological effectiveness (RBE) all push the physicist to look below the organ level—at least conceptually—before interpreting a dose.

This guide explains the physics that separates alpha dosimetry from beta dosimetry, derives a worked single-track microdosimetric dose, and connects the macroscopic MIRD calculation to the microscopic picture and to the regulatory framework. DRPS supports facilities building theranostics programs through its PET/CT and nuclear medicine physics and medical physicist consulting services across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Topic Explanation

What makes an alpha particle different

An alpha particle is a helium nucleus—two protons and two neutrons—emitted with several MeV of kinetic energy. Two physical properties dominate its dosimetry: ^{1, 2}

• Short range. Alpha particles from therapeutic nuclides carry roughly 5 to 8.5 MeV and travel only tens of micrometres in soft tissue—on the order of a few cell diameters. Per NIST stopping-power and range data, an alpha of about 5.7 MeV (the principal alpha in the radium-223 chain) has a range on the order of 50 µm in soft tissue. ³ That means an alpha emitter bound to a cell deposits essentially all of its energy in that cell and its immediate neighbors.
• High LET. Because that energy is dumped over such a short path, the linear energy transfer is on the order of 80 keV/µm—about two to three orders of magnitude higher than a typical beta particle (~0.2 keV/µm). The result is dense, clustered DNA damage, dominated by double-strand breaks that the cell cannot reliably repair. ²

These two facts explain why TAT can sterilize cells that resist beta or photon radiation, including hypoxic cells, and why only a handful of tracks—sometimes just one—through a nucleus can be lethal. ²

The two scales of alpha dose

Nuclear medicine dosimetry usually works at the macroscopic scale: the mean absorbed dose to an organ or lesion, computed with the MIRD schema. That is the right tool when energy deposition is smooth across the target, as it largely is for penetrating betas and photons.

Alpha particles break that assumption. When the range is smaller than the target, or when only a few decays occur in a small target, the dose becomes stochastic: whether a given cell is hit—and how many times—varies randomly. The macroscopic average can hide the fact that some nuclei receive several lethal tracks while others receive none. Describing that distribution is the domain of microdosimetry, which uses quantities such as specific energy (energy per unit mass deposited in a single microscopic target) and lineal energy. ¹ For routine therapy planning, physicists still compute an average absorbed dose and apply an RBE factor, but the microdosimetric picture explains why that works and where it can mislead. For the organ-level machinery that underlies the macroscopic calculation, see our companion articles on the MIRD schema for internal dosimetry and voxel-based dosimetry.

Key Technical Principles

Alpha versus beta: a side-by-side

The table makes the clinical logic explicit: alpha therapy concentrates lethal damage in the targeted cell and spares tissue a few cell-widths away, provided the targeting is specific. ^{1, 2} It also shows why the two radiation types cannot share a single dosimetry recipe. For isotope-specific therapy context, see actinium-225 targeted alpha therapy, radium-223 dichloride therapy physics and safety, and astatine-211 targeted alpha therapy.

Weighting factor versus RBE

Two different numbers describe alpha "quality," and conflating them is a common error:

• The radiation weighting factor for radiation protection is 20 for alpha particles (ICRP Publication 103). It converts absorbed dose (gray) to equivalent dose (sievert) for stochastic-risk estimation, and is a conservative, fixed protection quantity. ⁴
• The relative biological effectiveness (RBE) for therapy is measured experimentally and lands at roughly 3 to 7 depending on the endpoint and dose; a value near 5 is commonly used clinically to compute an RBE-weighted dose. ^{1, 5}

A therapy dosimetry report should quote absorbed dose in gray and, where it applies an RBE, state the value and endpoint—never substitute the protection weighting factor of 20 for a therapeutic RBE.

Macroscopic dose: MIRD with the full chain

At the organ or lesion scale, the mean absorbed dose follows the MIRD formalism:

where $\tilde{A}(r_S)$ is the time-integrated activity in each source region and $S(r_T\leftarrow r_S)$ is the radionuclide-specific S-value. For alpha self-dose the absorbed fraction is effectively one—the alpha range is far smaller than any organ—so the alpha S-value is dominated by energy deposited locally. ¹

The decisive subtlety is the decay chain. Therapeutic alpha emitters do not decay in a single step. Radium-223, for example, proceeds Ra-223 → Rn-219 → Po-215 → Pb-211 → Bi-211 → Tl-207/Po-211 → stable Pb-207, releasing four alpha particles plus beta and photon emissions along the way; actinium-225 similarly reaches bismuth-213 and beyond through several alpha-emitting daughters. ⁶ Most of the delivered energy comes from the daughters, so S-value sets and dose estimates must include the whole chain. ⁶ Daughters can also physically relocate after the parent decays—nuclear recoil can break the chelator bond—so their biodistribution may differ from the parent's, a genuine dosimetric and radiation-safety concern.

Microscopic dose: a worked single-track example

To see why alpha dose is stochastic, compute the specific energy deposited by one alpha traversal of a cell nucleus. Model the nucleus as a sphere of diameter $d=8\mu \text{m}$ (radius $r=4\mu \text{m}$) with unit density. Its mass is

The mean chord length of a convex body (Cauchy's theorem, $\bar{\ell }=4V/S$) for a sphere is $\frac{2}{3}d=5.33\mu \text{m}$. With an LET of about 80 keV/µm, a single traversal deposits

so the single-event specific energy is

One alpha track through one nucleus delivers about a quarter of a gray. ¹ A cell that happens to be traversed a few times receives a dose that is lethal many times over, while an untraversed neighbor receives essentially nothing from that decay. That is the stochastic reality the organ-average dose smooths over—and the reason uniform targeting, not just total administered activity, governs the outcome.

Clinical Impact

What measured alpha dosimetry looks like

Image-based alpha dosimetry is hard because the usable photon yield is small, but it has been done. In a radium-223 pharmacokinetic study, the calculated absorbed doses were about 0.76 Gy/MBq to osteogenic cells and about 0.09 Gy/MBq to red marrow, with roughly 85% of the injected activity retained in the body at 24 hours and the great majority taken up by bone. ⁷ A separate lesion-dosimetry study measured a mean effective half-life of about 8.2 days and an absorbed dose of about 0.7 Gy to bone metastases after the first injection; applying an alpha RBE of 5, the authors reported an RBE-weighted dose of roughly 899 mGy/MBq and a cumulative RBE-weighted lesion dose near 19 Gy over a full six-injection course. ⁵ These numbers show both the feasibility and the dominant uncertainty: the RBE factor you choose moves the biologically meaningful dose by a factor of several.

The organ at risk is usually marrow

Because alpha emitters so often target or transit bone, the red marrow is frequently the dose-limiting organ. Monte Carlo S-value work for radium-223 is explicitly motivated by the need to respect a marrow absorbed-dose constraint on the order of 2 Gy, and shows that body habitus changes the marrow dose for the same administered activity. ⁶ This is why administered activity for radium-223 is prescribed per body weight and why marrow dosimetry—not tumor dose—often sets the practical ceiling.

A note on administered activity and calibration

The approved radium-223 dichloride regimen is 55 kBq per kilogram of body weight, given every four weeks for six injections. ⁸ Earlier dosimetry studies, including those cited above, used a 50 kBq/kg prescription under a previous activity-standard calibration; the change to 55 kBq/kg reflects a standardization update rather than a different amount of physical activity. ⁸ When comparing published dose-per-MBq figures, confirm which calibration and prescription applied.

Practical Optimization Tips

• Report absorbed dose in gray, and state any RBE explicitly. Give the RBE value and endpoint; do not use the protection weighting factor of 20 as a therapy RBE. ^{4, 5}
• Model the whole decay chain. Include daughter alphas and photons, and consider daughter redistribution after recoil; a parent-only estimate understates and mislocates dose. ⁶
• Identify the dose-limiting organ early. For bone-seeking alpha agents, red marrow is usually limiting; prescribe and verify against a marrow constraint. ⁶
• Use quantitative imaging where feasible. Low photon yields make imaging hard, but calibrated planar or SPECT/CT quantification of the parent or an imageable daughter supports patient-specific dose estimates. ⁵ See voxel-based dosimetry.
• Keep microdosimetry in view for interpretation. When targeting is heterogeneous or activity is low, average dose can overstate tumor control probability; microdosimetric or microdosimetric-kinetic-model approaches explain the spread. ^{1, 9, 10}
• Match contamination controls to the hazard. Alpha contamination is an internal-dose hazard that a standard exposure-rate survey will not reveal; see RPT shielding for Lu-177, Ra-223, and Ac-225.

Regulatory Considerations

Administering an alpha-emitting radiopharmaceutical is medical use of byproduct material and must be performed under 10 CFR Part 35 or the equivalent Agreement State program. The dosimetry, where required, and the radiation-safety controls should be documented and defensible. ^{11, 12}

Key frameworks to reference:

• 10 CFR Part 35 — Medical Use of Byproduct Material, which governs authorized users, written directives, and the radiation safety officer's responsibilities for therapy radionuclides. Radium-223 dichloride is administered under its approved framework, while newer alpha agents are generally handled under the emerging-use provisions of 10 CFR 35.1000. ¹¹ See our overview of 10 CFR 35.1000 emerging medical uses.
• 10 CFR Part 20 — Standards for Protection Against Radiation, which sets occupational and public dose limits and the framework for contamination control and waste. ¹²
• ICRP Publication 103 (radiation weighting factor of 20 for alpha) and ICRP Publication 107 (nuclear decay data), the reference data underlying protection and dosimetry calculations. ⁴

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington DC and Delaware are regulated directly by the NRC. A facility must verify which authority issues its license before relying on any dosimetry or release assumption. Facilities building a theranostics program should connect dosimetry to radioactive material license support, radiation safety officer guidance, and PET/CT and nuclear medicine physics.

Frequently Asked Questions (FAQs)

Why do alpha emitters need different dosimetry than beta emitters?

Alpha particles have a very short range (tens of micrometers, a few cell diameters) and a very high linear energy transfer (LET), so their energy is deposited densely and locally rather than spread over many cells like beta particles. This means the absorbed dose is highly nonuniform at the cellular scale, a single track can deliver a large dose to one cell while a neighbor receives nothing, and the biological effect per unit dose is several times greater. Organ-average absorbed dose alone can therefore misrepresent the biological effect, so alpha dosimetry pairs macroscopic MIRD dose with microdosimetry and an alpha-specific relative biological effectiveness.

What is the radiation weighting factor for alpha particles?

ICRP Publication 103 assigns alpha particles a radiation weighting factor of 20 for radiation-protection equivalent dose. That means, for protection purposes, 1 gray of alpha absorbed dose is treated as 20 sieverts of equivalent dose. The weighting factor is a protection quantity, not a therapy relative biological effectiveness; in therapy, measured RBE values of roughly 3 to 7 are used instead, depending on the endpoint.

What is the relative biological effectiveness (RBE) of alpha particles?

Experimental cell and animal data place the acute RBE of alpha particles at roughly 3 to 7 relative to beta or external-beam radiation, depending on the endpoint and dose. A value near 5 is commonly used in clinical alpha-therapy dosimetry to convert absorbed dose into an RBE-weighted dose. RBE is distinct from the radiation-protection weighting factor of 20.

How is the absorbed dose from an alpha emitter calculated?

At the organ or lesion level, the MIRD schema is used: the mean absorbed dose equals the time-integrated activity in each source region multiplied by radionuclide-specific S-values. Because the alpha range is far shorter than an organ, essentially all alpha energy is deposited within the source region (the absorbed fraction is near one for self-dose). For a realistic estimate the decay chain must be included, since daughters often contribute additional alpha and photon energy, and the biodistribution of the daughters may differ from the parent.

Why does the alpha decay chain matter for dosimetry?

Alpha emitters used in therapy, such as Ac-225 and Ra-223, decay through a chain that emits several alpha particles and some photons before reaching a stable nuclide. Most of the delivered energy comes from the daughters, not the parent alone, and the daughters can relocate after the parent decays (recoil can break the chelator bond). A dosimetry estimate that counts only the parent underestimates dose and can misplace it, so the full chain and possible daughter redistribution should be modeled.

What is microdosimetry and when is it needed?

Microdosimetry describes the stochastic deposition of energy in microscopic targets such as a cell or cell nucleus, using quantities like specific energy (energy per unit mass in a single target) and lineal energy. It is needed when the biological target is small or when few decays occur, because then the average absorbed dose no longer predicts outcome—some targets are hit and others are missed. For routine therapy planning, average absorbed dose with an RBE factor is often used, but microdosimetry explains why alpha therapy is potent and why uniform targeting matters.

Does targeted alpha therapy fall under NRC medical-use rules?

In the United States, administering an alpha-emitting radiopharmaceutical is medical use of byproduct material under 10 CFR Part 35 (or the equivalent Agreement State program). Ra-223 dichloride has its own approved framework, while newer alpha agents are generally handled under emerging-use provisions (10 CFR 35.1000). The program must address authorized users, written directives, dosimetry where required, contamination control, waste, and patient-release instructions based on measured dose rates.

Key Takeaways

• Alpha dose is a two-scale problem. Macroscopic MIRD absorbed dose must be read alongside the microscopic, stochastic picture that microdosimetry describes.
• Short range and high LET drive everything. Energy deposited over a few cell diameters at ~80 keV/µm produces dense, largely irreparable DNA damage—and profoundly nonuniform dose.
• Weighting factor is not RBE. ICRP 103 assigns a protection weighting factor of 20; therapy uses a measured RBE of roughly 3–7 (often 5). State which you mean.
• Model the whole decay chain. Daughters carry most of the energy and can relocate; parent-only dosimetry is wrong.
• Marrow is usually limiting. For bone-seeking alpha agents, red marrow absorbed dose, not tumor dose, often sets the ceiling.
• A single track matters. A worked estimate shows ~0.25 Gy from one alpha traversal of an 8-µm nucleus—why targeting specificity governs outcome.

Conclusion

Targeted alpha therapy rewards precision at a scale most nuclear medicine dosimetry never has to consider. The organ-level MIRD dose is still the backbone of a report, but for alpha emitters it is only half the story: the same gray delivered by dense, short alpha tracks is biologically worth several grays of beta radiation, and it is distributed so unevenly that whether a cell lives or dies is partly a matter of how many tracks happened to cross it.

A defensible alpha-dosimetry program therefore reports absorbed dose in gray, states its RBE assumption and endpoint, models the full decay chain and its daughters, identifies the dose-limiting organ—usually marrow—and keeps the microdosimetric picture in view when targeting is heterogeneous. Done that way, the physics that makes alpha therapy powerful becomes something a program can measure, document, and defend.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and theranostics programs put alpha-emitter dosimetry on a defensible footing. This includes PET/CT and nuclear medicine physics support, dosimetry workflow review, quantitative-imaging calibration, contamination-control and waste assessments, radioactive material license support, and radiation safety officer program guidance aligned with NRC and Agreement State requirements.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

Alpha therapy is unforgiving of vague dosimetry. Getting the absorbed dose, the RBE, the decay chain, and the limiting organ right is what turns a potent radionuclide into a controlled, documentable treatment.

Related Resources

• MIRD schema for internal dosimetry
• Voxel-based dosimetry for radiopharmaceutical therapy
• Actinium-225 targeted alpha therapy
• Radium-223 dichloride therapy: physics and safety
• Astatine-211 targeted alpha therapy
• RPT shielding for Lu-177, Ra-223, and Ac-225
• PET/CT and nuclear medicine physics
• Medical physicist consulting

References

1. Sgouros G, Roeske JC, McDevitt MR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51(2):311-328. doi:10.2967/jnumed.108.058651. doi.org
2. Sgouros G. Alpha-particles for targeted therapy. Adv Drug Deliv Rev. 2008;60(12):1402-1406. doi:10.1016/j.addr.2008.04.007. doi.org
3. National Institute of Standards and Technology. ASTAR: Stopping-Power and Range Tables for Helium Ions. NIST Standard Reference Database 124. nist.gov
4. International Commission on Radiological Protection. ICRP Publication 103: The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37(2-4). icrp.org
5. Pacilio M, Ventroni G, De Vincentis G, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride. Eur J Nucl Med Mol Imaging. 2016;43(1):21-33. doi:10.1007/s00259-015-3150-2. doi.org
6. Silva CCO, da Silva AX, Braz D, Lima LFC, Segars WP, de Sá LV. S-values for radium-223 and absorbed dose estimates for RaCl2 using three computational phantoms. Appl Radiat Isot. 2022;189:110387. doi:10.1016/j.apradiso.2022.110387. doi.org
7. Yoshida K, Kaneta T, Takano S, et al. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases. Ann Nucl Med. 2016;30(7):453-460. doi:10.1007/s12149-016-1093-8. doi.org
8. U.S. Food and Drug Administration. Xofigo (radium Ra 223 dichloride) injection, prescribing information. accessdata.fda.gov
9. Sato T, Furuta T, Liu Y, et al. Individual dosimetry system for targeted alpha therapy based on PHITS coupled with microdosimetric kinetic model. EJNMMI Phys. 2021;8(1):4. doi:10.1186/s40658-020-00350-7. doi.org
10. Parisi A, Furutani KM, Beltran CJ. On the calculation of the relative biological effectiveness of ion radiation therapy using a biological weighting function, the microdosimetric kinetic model (MKM), and subsequent corrections. Phys Med Biol. 2022;67(9). doi:10.1088/1361-6560/ac5fdf. doi.org
11. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
12. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov